Source
From GlobeNewswire
24 releases originally issued via GlobeNewswire. The issuing organizations are responsible for their content.
CARRIAGE SERVICES INC
Carriage Services Announces Third Quarter 2026 Results, Updates 2026 Guidance
electroCore Announces Third Quarter 2026 Financial Results
Third quarter 2026 net sales of $9.7 million, an increase of 12% over $8.7 million in the third quarter of 2025
Cytek Biosciences Reports Third Quarter 2026 Financial Results
TWFG Announces Third Quarter 2026 Results
– Total Revenues increased 24.6% for the quarter over the prior year period to $79.9 million –
Pennant Reports Third Quarter 2026 Results
Conference Call and Webcast scheduled for tomorrow, November 5, 2026 at 10:00 am MT
Aprea Therapeutics Announces Third Quarter 2026 Financial Results
Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026)…
Twin Disc Announces First Quarter Results
Riot Platforms Reports Third Quarter 2026 Financial Results and Strategic Highlights
Executed a 15-year, 910 critical IT MW triple-net powered land lease with a leading Frontier AI Lab at Corsicana, representing approximately $28…
Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Achieved $60.1 million in RYTELO® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026
Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis
BioCryst Reports Third Quarter 2026 Financial Results
Total net revenue of $180.3 million and ORLADEYO® net revenue of $174.8 million —
Ridgepost Capital Reports Third Quarter 2026 Financial Results
Lime Announces Third Quarter 2026 Financial Results
Record Third Quarter Revenue of $361 Million, Up 20% YoY
INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE
FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three…
Neostellar Capital Corp. Reports Third Quarter 2026 Financial Results
Net Asset Value of $12.64 Per Share as of September 30, 2026